Quince Therapeutics Inc

Quince Therapeutics Inc has a market capitalization of $19.23 million and a price-to-book ratio of 0.41, indicating that the company is trading at a significant discount to its book value. The company's liquidity position is characterized by a current ratio of 6.15, suggesting a strong ability to meet short-term obligations, although it has negative net cash after subtracting total debt. The company's profitability is currently negative, with a return on equity of -59.04% and a return on assets of -20.57%, which are well below the typical performance metrics for the biotechnology industry. The company reported a net loss of $27.73 million and an operating loss of $28.19 million, reflecting ongoing financial challenges. Geographically and segment-wise, Quince Therapeutics Inc's revenue concentration is not disclosed in the available data. However, the company's operations are primarily focused on the development of immunotherapies, with no specific geographic breakdown provided in the financial snapshot. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is negative at -$17.09 million, and its free cash flow is also negative at -$27.72 million, indicating that the company is not generating sufficient cash from operations to sustain its activities. The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's financial vulnerability. The company's debt-to-equity ratio of 0.29 suggests a relatively low level of leverage, but the negative cash flows indicate potential liquidity constraints. Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. The company's analyst estimates suggest a mean price target of $80.00, with a mean recommendation of 3.00, indicating a neutral stance from analysts.